The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin
Open accessAbstract
Increased platelet activation is recognized in patients with sickle cell disease (SCD), but its pathogenesis and clinical relevance remain uncertain. Pulmonary arterial hypertension (PAH), an important complication of SCD, is characterized by a proliferative pulmonary vasculopathy, in situ thrombosis, and vascular dysfunction related to scavenging of nitric oxide (NO) by hemoglobin released into blood plasma during intravascular hemolysis. We investigated links between platelet activation, PAH and NO scavenging in patients with SCD. Platelet activation marked by activated fibrinogen receptor correlated to the severity of PAH (r = 0.58, P < .001) and to laboratory markers of intravascular hemolysis, such as reticulocyte count (r = 0.44, P = .02). In vitro exposure of platelets to pathologically relevant concentrations of cell-free hemoglobin promoted basal- and agonist-stimulated activation and blocked the inhibitory effects on platelet activation by an NO donor. In patients with SCD, administration of sildenafil, a phosphodiesterase-5 inhibitor that potentiates NO-dependent signaling, reduced platelet activation (P = .01). These findings suggest a possible interaction between hemolysis, decreased NO bioavailability, and pathologic platelet activation that might contribute to thrombosis and pulmonary hypertension in SCD, and potentially other disorders of intravascular hemolysis. This supports a role for NO-based therapeutics for SCD vasculopathy. This trial was registered at www.clinicaltrials.gov as no. NCT00352430.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taken together and in the context of the well-described hemostatic activation at baseline and its increase during VOC in SCD (91), these findings suggest that the prothrombotic environment of VOC and ACS is conducive to pulmonary thrombosis.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [91]
In the citing paper
“Experimental studies demonstrated that PLTs can be activated via pharmacological inhibition of endogenous NO production in humans (159), leading to hypercoagulability and thrombotic complications (186).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [186]
Citations
Cites
Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly
Beckman, J. S., & Koppenol, W. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.5.c1424 · Cited by 5,513 · cited 1×
“Intravascular hemolysis releases hemoglobin and arginase into blood plasma, where the former scavenges NO, and the latter depletes plasma of L-arginine, the obligate substrate for NO synthase, with both processes severely reducing NO bioavailability.(11;19;20) In a normal vascular environment, NO synthesized by the en…”
BackgroundRother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Self-citationCell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationBiosynthesis and Metabolism of Endothelium-Derived Nitric Oxide
Ignarro, L. J. (1990) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.30.040190.002535 · Cited by 1,314
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., et al. (2002) · Nature Medicine · doi:10.1038/nm799 · Cited by 1,097 · cited 1×
“Healthy human hemoglobin was purified from red blood cells by hypotonic lysis and differential centrifugation as previously described.(31) Monoclonal antibodies: PerCp-labeled anti-CD61, FITC-labeled PAC1, PElabeled anti-CD62P, PE-labeled mouse anti-human IgG1 antibodies were purchased from Becton Dickinson (San Jose,…”
MethodMorris, C. R. (2005) · JAMA · doi:10.1001/jama.294.1.81 · Cited by 763 · cited 1×
“In this model, reduced nitric oxide bioavailability and endothelial dysfunction results in the clinical development of pulmonary hypertension.(11;28;44;45) Increased platelet activation is another well described consequence of endothelial dysfunction and decreased NO bioavailability.”
BackgroundPanza, J. A., Casino, P. R., Kilcoyne, C. M., & Quyyumi, A. A. (1993) · Circulation · doi:10.1161/01.cir.87.5.1468 · Cited by 707 · cited 1×
“There is evidence in other diseases characterized by vascular dysfunction and impaired NO bioavailability that platelets are pathologically activated.(27;28) Additionally, platelet activation has been observed in patients with pulmonary hypertension associated to β thalassemia.”
BackgroundEndothelium‐derived nitric oxide: actions and properties
Ignarro, L. J. (1989) · The FASEB Journal · doi:10.1096/fasebj.3.1.2642868 · Cited by 679
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661 · cited 1×
“Although its pathogenesis is likely multifactorial, PAH in SCD is epidemiologically associated with multiple markers of intravascular hemolysis.(11;12;18) Intravascular hemolysis releases hemoglobin and arginase into blood plasma, where the former scavenges NO, and the latter depletes plasma of L-arginine, the obligat…”
BackgroundSelf-citation
Research works printed but not linked: 2
- Adedeji, 2001, Pulmonary thrombotic arteriopathy in patients with sickle cell disease., Arch Pathol Lab Med, 125, 1436, 10.5858/2001-125-1436-PTAIPW · DOI
- Haque, 2002, Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases., Hum Pathol, 33, 1037, 10.1053/hupa.2002.128059 · DOI · Paper page
Cited by
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationSchaer, D. J., Buehler, P. W., Alayash, A. I., Belcher, J. D., & Vercellotti, G. M. (2013) · Blood · doi:10.1182/blood-2012-11-451229 · Cited by 754
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 536
Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
“Experimental studies demonstrated that PLTs can be activated via pharmacological inhibition of endogenous NO production in humans (159), leading to hypercoagulability and thrombotic complications (186).”
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citation
Metadata
- Authors
- Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J.
- Affiliations
- Vascular Medicine Branch of the National Heart, Lung, and Blood Institute,
- National Heart, Lung, and Blood Institute (US)
- National Institutes of Health (US)
- Johns Hopkins University (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-09-15
- Volume
- 110
- Issue
- 6
- Pages
- 2166-2172
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC1976348
- OpenAlex
- W2054224182
- Cited by
- 384
- References
- 59
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 12 · 2023: 17 · 2022: 16 · 2021: 24 · 2020: 26 · 2019: 28 · 2018: 27 · 2017: 21 · 2016: 21 · 2015: 14 · 2014: 16 · 2013: 28 · 2012: 18
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (Z99 HL999999)
- National Heart, Lung, and Blood Institute (ZIAHL006014)
- National Cancer Institute (T32 CA60441, T32CA060441)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD001399)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- sickle cell disease, platelet activation, pulmonary arterial hypertension, hemolysis, nitric oxide scavenging, free hemoglobin, intravascular hemolysis, fibrinogen receptor, sildenafil, nitric oxide bioavailability, thrombosis, pulmonary vascular disease
- MeSH terms
- Sildenafil Citrate, Adult, Anemia, Sickle Cell, Female, Flow Cytometry, Hemoglobins, Hemolysis, Humans, Hypertension, Pulmonary, Male, Nitric Oxide, Phosphodiesterase Inhibitors, Piperazines, Purines, Sulfones, Thrombosis, 3',5'-Cyclic-GMP Phosphodiesterases, Platelet Activation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. https://app.cochat.ai/papers/10.1182/blood-2006-12-061697
- The paper
- Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2007). Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. https://doi.org/10.1182/blood-2006-12-061697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.